Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With Metastatic Castrate Resistant Prostate Cancer

NCT03432949 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT03432949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03432949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With Metastatic Castrate Resistant Prostate Cancer
Lead sponsor
University Health Network, Toronto
Phase
Phase 4
Overall status
Unknown status
Start date
February 23, 2018
Completion date
July 30, 2024
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer